Milestone

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Retrieved on: 
Thursday, February 29, 2024

MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate panel discussion at the TD Cowen 44th Annual Health Care Conference on March 5, 2024, at 10:30am ET.

Key Points: 
  • MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate panel discussion at the TD Cowen 44th Annual Health Care Conference on March 5, 2024, at 10:30am ET.
  • The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone's website.
  • www.milestonepharma.com

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Retrieved on: 
Thursday, February 29, 2024

MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 16,666,667 of its common shares (the “Shares”) at a public offering price of $1.50 per share and (ii) in lieu of common shares, pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such pre-funded warrant (“Pre-Funded Warrants” and, together with the Shares the “Securities”).

Key Points: 
  • MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 16,666,667 of its common shares (the “Shares”) at a public offering price of $1.50 per share and (ii) in lieu of common shares, pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such pre-funded warrant (“Pre-Funded Warrants” and, together with the Shares the “Securities”).
  • The proceeds to Milestone from the Offering, before deducting underwriting commissions and offering expenses payable by Milestone, are expected to be approximately $30.0 million.
  • In addition, Milestone has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 common shares at the public offering price, less underwriting commissions.
  • The Offering is expected to close on or about March 4, 2024, subject to satisfaction of customary closing conditions.

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Retrieved on: 
Wednesday, February 28, 2024

MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares (the “Shares,”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares (“Pre-Funded Warrants” and, together with the Shares, the “Securities”).

Key Points: 
  • MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares (the “Shares,”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares (“Pre-Funded Warrants” and, together with the Shares, the “Securities”).
  • In addition, Milestone expects to grant the underwriters a 30-day option to purchase a number of additional common shares equal to 15% of the Securities offered in the Offering.
  • All Securities to be sold in the Offering will be sold by the Company.
  • The Offering is subject to market and other conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

Gracell Biotechnologies Acquisition Completed

Retrieved on: 
Thursday, February 22, 2024

The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).

Key Points: 
  • The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).
  • As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.
  • Such letters of transmittal must be completed before such holders can receive the applicable merger consideration.
  • Certificated ADS holders should wait to receive the letters of transmittal before surrendering their ADSs.

RFG Advisory Bolsters Executive Roster by Adding Abby Salameh and Two Tenured Leaders

Retrieved on: 
Thursday, March 7, 2024

RFG Advisory , (“RFG”) an innovator in the wealth management industry committed to serving independent financial advisors and their clients, today announced three key appointments to its executive team.

Key Points: 
  • RFG Advisory , (“RFG”) an innovator in the wealth management industry committed to serving independent financial advisors and their clients, today announced three key appointments to its executive team.
  • Abby Salameh , an industry pioneer with over 25 years of building growth services for independent financial advisors, joins RFG as chief growth officer.
  • Recognized as the 2023 WeathManagement.com Technology CMO of the Year1, Salameh is set to drive advisor recruitment, marketing and organic growth among RFG’s existing network of advisors.
  • “RFG is the most industry awarded firm advisors have never heard of and we are about to change that,” said Salameh.

Milestone Appoints Barbara Burger to Board

Retrieved on: 
Tuesday, February 27, 2024

Milestone Environmental Services, LLC (“Milestone” or the “Company”), a leading environmental services and carbon management company and the largest energy waste sequestration company in the United States, today announced that Barbara J. Burger, PhD, has been appointed to the Company’s Board of Managers, effective February 17, 2024.

Key Points: 
  • Milestone Environmental Services, LLC (“Milestone” or the “Company”), a leading environmental services and carbon management company and the largest energy waste sequestration company in the United States, today announced that Barbara J. Burger, PhD, has been appointed to the Company’s Board of Managers, effective February 17, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240227696477/en/
    Barbara J. Burger, PhD, who joined Milestone Environmental Services' Board of Managers on February 17, 2024, is a former Chevron executive with 36 years of industry and energy transition expertise.
  • (Photo: Business Wire)
    “I am very pleased to welcome Dr. Barbara Burger to the Milestone Board and look forward to her invaluable insights and contributions,” said Milestone President and CEO Gabriel Rio .
  • Dr. Burger also remains committed to the National Renewable Energy Laboratory, Activate, and is the President of the Board of Directors of the Houston Symphony.

Milestone Appoints Josh King as Chief Financial Officer; Announces Retirement of Frank W. Schageman

Retrieved on: 
Wednesday, February 14, 2024

Mr. King joins Milestone’s executive leadership team and replaces Frank W. Schageman, who will retire from the Company after a transition period at the end of the first quarter of 2024.

Key Points: 
  • Mr. King joins Milestone’s executive leadership team and replaces Frank W. Schageman, who will retire from the Company after a transition period at the end of the first quarter of 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240214483841/en/
    Josh King joins Milestone Environmental Services as Chief Financial Officer and as a member of the Executive Leadership Team, effective January 18, 2024.
  • (Photo: Business Wire)
    In his new role, Mr. King is responsible for the financial aspects of Milestone and its subsidiaries.
  • “I am thrilled to welcome Josh to Milestone,” said Milestone President and CEO Gabriel Rio .

Milestones Drives Strong Momentum with 513% Increase of Consumers on Platform

Retrieved on: 
Monday, January 22, 2024

“We are excited about the momentum we are seeing around our homeowner engagement offerings and we’re just getting started,” said Dustin Gray, CEO of Milestones.

Key Points: 
  • “We are excited about the momentum we are seeing around our homeowner engagement offerings and we’re just getting started,” said Dustin Gray, CEO of Milestones.
  • Since then, Milestones experienced a 513% increase in new consumers on the platform, driven in part by the strategic expansion of top-producing real estate teams and regional mortgage lenders that led to a 41% increase in customer growth.
  • “These recent offerings represent the beginning of increased demand for those launching Milestones to be first to market to get homeowners on our branded solution.
  • This early reaction to consumers on the platform is bringing praise for what’s to come, setting new standards for consumer engagement and industry innovation,” said Ashley Terrell-Kayiran, Chief Revenue Officer of Milestones.

Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations: Investors Who Have Lost Money Are Encouraged to Contact the Firm

Retrieved on: 
Thursday, January 18, 2024

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations.

Key Points: 
  • BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations.
  • Investors who have lost money in their Milestone Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses.
  • Anyone who purchased Milestone Pharmaceuticals, Inc. stock and has lost money may be eligible, whether or not they have sold their investment.
  • Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST

Retrieved on: 
Saturday, January 6, 2024

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21411 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.